GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of ...